Christian Todd Nichols Sells 7,576 Shares of Alkermes (NASDAQ:ALKS) Stock

Posted by Brian Himes on Aug 17th, 2026

Alkermes plc (NASDAQ:ALKS – Get Free Report) SVP Christian Todd Nichols sold 7,576 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $49.23, for a total transaction of $372,966.48. Following the sale, the senior vice president owned 102,193 shares of the company’s stock, valued at approximately $5,030,961.39. This represents a 6.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alkermes Stock Performance

Alkermes stock traded up $0.79 during midday trading on Monday, hitting $49.85. 763,840 shares of the company’s stock were exchanged, compared to its average volume of 2,197,302. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.85 and a current ratio of 2.30. The stock has a market cap of $8.36 billion, a price-to-earnings ratio of 131.19 and a beta of 0.34. Alkermes plc has a 12-month low of $25.17 and a 12-month high of $55.67. The firm’s 50 day simple moving average is $49.98 and its 200 day simple moving average is $39.45.

Hedge Funds Weigh In On Alkermes

Institutional investors and hedge funds have recently made changes to their positions in the stock. Profund Advisors LLC lifted its holdings in Alkermes by 80.9% in the 4th quarter. Profund Advisors LLC now owns 80,624 shares of the company’s stock worth $2,256,000 after buying an additional 36,067 shares in the last quarter. UBS Group AG increased its position in shares of Alkermes by 237.4% during the fourth quarter. UBS Group AG now owns 2,544,895 shares of the company’s stock worth $71,206,000 after acquiring an additional 1,790,729 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of Alkermes by 21.0% in the fourth quarter. Fisher Asset Management LLC now owns 390,493 shares of the company’s stock worth $10,926,000 after acquiring an additional 67,745 shares in the last quarter. Abacus FCF Advisors LLC purchased a new position in Alkermes in the fourth quarter valued at about $6,141,000. Finally, S&CO Inc. acquired a new stake in Alkermes during the 2nd quarter valued at approximately $12,824,000. 95.21% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have commented on ALKS. Needham & Company LLC upped their price objective on Alkermes from $61.00 to $62.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Royal Bank Of Canada increased their price target on Alkermes from $45.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, June 9th. UBS Group lifted their price objective on shares of Alkermes from $42.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Robert W. Baird boosted their price objective on shares of Alkermes from $48.00 to $58.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Finally, Bank of America restated an “underperform” rating on shares of Alkermes in a research note on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Alkermes has an average rating of “Moderate Buy” and a consensus price target of $54.56.

View Our Latest Stock Report on ALKS

About Alkermes

(Get Free Report)

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.